Core Insights - Tevogen Bio Holdings Inc. is focused on immunotherapy and artificial intelligence, with recent presentations highlighting their advancements in AI-driven technology for T cell therapies [1][3][4] Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company developing off-the-shelf, genetically unmodified precision T cell therapies aimed at treating infectious diseases and cancers [4] - The company has reported positive safety data from its proof-of-concept clinical trial and owns key intellectual property assets, including three granted patents and multiple pending patents related to artificial intelligence [4] Recent Developments - Mittul Mehta, the Chief Information Officer, presented at the AI x Bio Philly event, showcasing Tevogen.AI's technology that accelerates the discovery and development of precision T cell therapies [1][3] - The proprietary technology utilizes computational modeling to predict T cell receptor engagement with immunologically active HLA+ peptide complexes [3] Industry Context - The AI x Bio Philly event gathered innovators, entrepreneurs, and investors to discuss the impact of AI on biotechnology, indicating a growing intersection between these fields [2]
Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly's Leading AI Biotechs